Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
anti-IL-20 · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Anti-IL-20 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| A, HV | EXPERIMENTAL | Dose cohort 1 (3 subjects active, 1 placebo) |
| B, HV | EXPERIMENTAL | Dose cohort 2 (3 subjects active, 1 placebo) |
| C, HV | EXPERIMENTAL | Dose cohort 3 (3 subjects active, 1 placebo) |
| D, HV | EXPERIMENTAL | Dose cohort 4 (3 subjects active, 1 placebo) |
| E, HV | EXPERIMENTAL | Dose cohort 5 (3 subjects active, 1 placebo) |
| A, RA | EXPERIMENTAL | Dose cohort 1 (3 subjects active, 1 placebo) |
| B, RA | EXPERIMENTAL | Dose cohort 2 (3 subjects active, 1 placebo) |
| C, RA | EXPERIMENTAL | Dose cohort 3 (3 subjects active, 1 placebo) |
| Name | Type | Description |
|---|---|---|
| anti-IL-20 | DRUG | Anti-IL-20 injected subcutaneously (under the skin) with 1 dose once weekly during a 6 week period (in total 7 doses) at 2 dose levels. |
| placebo | DRUG | Placebo injected subcutaneously (under the skin) with 1 dose once weekly during a 6 week period (in total 7 doses) at 2 dose levels. |
Inclusion Criteria: * Informed consent obtained before any trial-related activities * A diagnosis of rheumatoid arthritis made at least 3 months prior to screening * Active rheumatoid arthritis, characterised by a DAS28 equal or above 3.2 * Methotrexate treatment (stable dose, equal or below 25 mg/...
Anti-IL-20 is an investigational small molecule being developed for inflammation, including rheumatoid arthritis. It is in Phase 1 clinical development and has been studied in healthy volunteers and patients with rheumatoid arthritis to evaluate safety and tolerability.
Anti-IL-20 is being developed by Novo Nordisk A/S, a biopharmaceutical company traded on the New York Stock Exchange under the ticker NVO.
Anti-IL-20 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 1 trials have been completed, both focused on safety and tolerability in healthy volunteers and patients with rheumatoid arthritis.
Anti-IL-20 has been studied in two completed Phase 1 trials. NCT00818064 evaluated safety and tolerability in healthy volunteers and patients with rheumatoid arthritis in the Netherlands. NCT01038674 evaluated safety and tolerability in patients with rheumatoid arthritis in Belgium and Poland.
Yes, anti-IL-20 is a small molecule therapeutic. It is being developed as an immunology treatment for inflammatory conditions, including rheumatoid arthritis.